Relationship Between Natural Killer Cells’ Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2
Study Information
Alliance Study ID: CALGB-20206
NCT Study ID (ClinicalTrials.gov): NCT00896701
Alliance Committee: Leukemia
Disease or Cancer Type: Leukemia & Myelodysplastic Syndromes (MDS)
Alliance Study Chair: Sherif S. Farag, MD, PhD
Status: COMPLETED
Study Description
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors predict response in patients previously treated with interleukin-2.
PURPOSE: This laboratory study is looking at the relationship between natural killer cells’ ability to kill leukemia cells and the outcome of patients with acute myeloid leukemia previously treated with interleukin-2.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information